[Treatment of severe steroid-refractory graft-versus-host disease with IL-2R alpha chain (CD25) monoclonal antibody].
To investigate the effects of IL-2R alpha chain (CD(25)) monoclonal antibody on severe steroid-refractory graft-versus-host disease (GVHD). Seventeen patients (18 times) with severe steroid-refractory GVHD were treated with intravenous drip of humanized CD(25) monoclonal antibody on day 1, 3 or 4, 8, 15 and 22. The cumulative scoring of GVHD and status of infection were observed, and laboratory tests, including blood counting and blood biochemical test were made before and 1, 4, 8, 15, 22, 29, 36, 43 and 50 days after the treatment. (1) Eleven of the eighteen case-times (61.1%) got complete relief, five (27.8%) GVHD got partial relief, and two (11.1%) failed to get relief. (2) Seven case-times (33.3%) had infection. (3) Relapse of GVHD occurred in four of the eleven case-times with complete relief (36.4%). (4) No infusion-related reaction was observed. The monoclonal antibody against IL-2 receptor alpha chain (CD(25)) has a marked effect upon severe steroid-refractory GVHD.